ARCHIVES

Cancer Groups Endorse Richard Pazdur for Head of FDA’s New Office of Oncology Drug Products. Five Candidates Are In the Running for the Job, Sources Said.

This article is from The Cancer Letter archive.

Vol. 31 No. 07 | February 18, 2005

Download PDF Visit The Full Archive

Related Articles

NCI Raises New Questions About Duke Genomics Research, Cuts Assay From Trial

May 14, 2010

Conversation with The Cancer Letter: Rosen’s New Role Is Part Of An Evolution Of Administrative Structure at City of Hope

November 1, 2013

Funding and Direction of IL-2/LAK Trials Questioned By DCT Board

March 3, 1989

Oxaliplatin Regimen May Beat Standard For Advanced Colorectal Cancer, NCI Says

May 3, 2002

In Brief: House, Senate Enact FY ’92 Budget Bills For NCI That Differ By $200 Million; Senate’s Is Higher

September 27, 1991

In Brief: Reginald Ho Assumes ACS Presidency; Board Calls On NCI To Fully Fund ASSIST Program

November 13, 1992